EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, SCLXW: Scilex Holding Company WT

07 Nov 25 15:47
LAST:

0.2389

CHANGE:
 0.02		OPEN:
0.2638		HIGH:
0.2638		ASK:
0.0000		VOLUME:
9.9K
CHG(%):
9.44		PREV:
0.2638		LOW:
0.2263		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
07 Nov 250.26380.26380.22630.238916.1K
06 Nov 250.29750.29750.21190.26383.8K
05 Nov 250.30000.30000.21000.250026.2K
04 Nov 250.20000.29750.17970.297430.1K
03 Nov 250.20100.25330.18000.22127.8K
31 Oct 250.27750.27750.17500.250062.8K
30 Oct 250.21110.26000.19020.22954.9K
29 Oct 250.17000.28420.17000.262549.6K
28 Oct 250.18000.20920.17010.200014.5K
27 Oct 250.18000.18000.17000.180064.8K

COMPANY PROFILE

Name:Scilex Holding Company WT
About:Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is headquartered in Palo Alto, California.
Sector:Healthcare
Address:960 San Antonio Road, Palo Alto, CA, United States, 94303
Website:https://www.scilexholding.com
CIK:0001820190
ISIN:US80880W2052
FIGI:BBG00YM315Z3

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:0.256.4%
MA10:0.240.2%
MA20:0.1925.7%
MA50:0.268.6%
MA100:0.3024.0%
MA200:0.2210.8%
STO9:38.90
STO14:63.44
RSI14:64.44 
WPR14:-35.56
MTM14:0.11
ROC14:0.80 
ATR:0.06 
Week High:0.3025.6%
Week Low:0.1836.5%
Month High:0.3025.6%
Month Low:0.1110.8%
Year High:0.65172.1%
Year Low:0.04537.1%